Clinical trial application for Sansheng Pharmaceutical Nafuramorphine Hydrochlorite (TRK-820) approved

Recently, SanshengPharmaceutical(http://(01530HK) announced that its clinicaltrial(http:// for clinicaltrials of thedrug(http:// for the treatment of itching in hemodialysis patientsthe oral dissomiasis tablets of nafurana morphine hydrochloric acid (TRK-820) was approved by the NationalMedicines(http://Regulatory Authority on September 16, 2019About TRK-820
TRK-820 is an exclusive licensed product (http:// of Sansheng Pharmaceuticals and Japan's Toray Industries, Inc 　　In January 2018, Toray Industries, Inc granted Sansheng Pharmaceuticals exclusive rights to develop and commercialize the formulation of several oral disintegrating tablet formulations of TRK-820 in the mainland of the People's Republic of China (excluding Hong Kong, Macau and Taiwan) 　　TRK-820 is a highly selective (kappa)-opioid receptor agonist developed by Toray 　　TRK-820's softcapsule form has been available in Japan since 2009 to treat hemodialysis-related uremia itching 　　Other indications of TRK-820, including itching in patients with chronic liver disease and itching in patients with peritoneal dialysis, were approved in Japan in 2015 and 2017, respectively